Polyclonal rabbit anti-human ovarian cancer globulins inhibit tumor growth through apoptosis involving the caspase signaling

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Zhang, Shuang ^a   Yu, Min ^a   Deng, Hongxin ^a   Shen, Guobo ^a   Wei, Yuquan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CASPASE 3; CASPASE 9; GLOBULIN;

ANIMAL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; DRUG EFFECT; DRUG SCREENING; FEMALE; HUMAN; METABOLISM; MOUSE; NUDE MOUSE; OVARY TUMOR; RABBIT; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTIBODIES; APOPTOSIS; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GLOBULINS; HUMANS; MICE; MICE, NUDE; OVARIAN NEOPLASMS; RABBITS; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901036142     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep04984     Document Type: Article

References (26)

1. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J Clin. 63, 11-30 (2013).
2. Yap, T. A., Carden, C. P. &Kaye, S. B. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer. 9, 167-81 (2009).
3. Kaye, S. B. et al. A randomized phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin-based therapy alone in patients with relapsed, platinum-sensitive ovarian cancer. Ann Oncol. 24, 145-52 (2013).
4. Aghajanian, C. et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 30, 2039-45 (2012).
5. Seiden, M. V. et al. Aphase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol. 104, 727-31 (2007).
6. Armstrong, D. K., White, A. J., Weil, S. C., Phillips, M. & Coleman, R. L. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer. Gynecol Oncol. 129, 452-8 (2013).
7. Bookman, M. A., Darcy, K. M., Clarke-Pearson, D., Boothby, R. A. & Horowitz, I. R. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol. 21, 283-90 (2003). (Pubitemid 46606157)
8. Mu, B. et al. Polyclonal rabbit anti-murine plasmacytoma cell globulins induce myeloma cells apoptosis and inhibit tumour growth in mice. Apoptosis. 16, 370-81 (2011).
9. Sharon, J. et al. Recombinant polyclonal antibodies for cancer therapy. J Cell Biochem. 96, 305-13 (2005). (Pubitemid 41437863)
10. Cannistra, S. A. Cancer of the ovary. N Engl J Med. 351, 2519-29 (2004).
11. Kipps, E., Tan, D. S. & Kaye, S. B. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer. 13, 273-82 (2013).
12. Reid, A., Vidal, L., Shaw, H. & de Bono, J. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu). Eur J Cancer. 43, 481-9 (2007). (Pubitemid 46178540)
13. Perren, T. J. et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl JMed. 365, 2484-96 (2011).
14. Sliwkowski, M. X. & Mellman, I. Antibody therapeutics in cancer. Science. 341, 1192-8 (2013).
15. Zhao, B. et al. Addressing genetic tumor heterogeneity through computationally predictive combination therapy. Cancer Discov. 4, 166-74 (2014).
16. Kim, R., Emi, M. & Tanabe, K. Cancer immunoediting from immune surveillance to immune escape. Immunology. 121, 1-14 (2007). (Pubitemid 46537674)
17. Park, S. et al. The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell. 18, 160-70 (2010).
18. Häusler, S. F. et al. Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion. Am J Transl Res. 6, 129-39 (2014).
19. Schiavoni, G. et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. 71, 768-78 (2011).
20. Gyrd-Hansen, M. & Meier, P. IAPs: from caspase inhibitors to modulators of NFkappaB, inflammation and cancer. Nat Rev Cancer. 10, 561-74 (2010).
21. Weston, V. J. et al. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood. 116, 4578-87 (2010).
22. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 366, 2443-54 (2012).
23. Heo, D. S. et al. Evaluation of tetrazolium-based semiautomatic colorimetric assay for measurement of human antitumor cytotoxicity. Cancer Res. 50, 3681-90 (1990).
24. Xu, N. et al. Human alpha-defensin-1 inhibits growth of human lung adenocarcinoma xenograft in nude mice. Mol Cancer Ther. 7, 1588-97 (2008).
25. Vermes, I., Haanen, C., Steffens-Nakken, H. & Reutelingsperger, C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods. 184, 39-51 (1995).
26. Liu, J. et al. TGF-b blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma. Proc Natl Acad Sci USA. 109, 16618-23 (2012).